Recent studies have shown that ICI monotherapy and ICI in combination with chemotherapy improved survival in advanced NSCLC, with some trials showing an association among programmed death-ligand 1 (PD-L1) expression and treatment benefit (17–23). This evidence concerns the gene CD274 and non-small cell lung carcinoma.